{
  "citations": [],
  "guideline": {
    "objCls": "Guideline Annotation",
    "id": "PA166222201",
    "name": "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "alternateDrugAvailable": false,
    "cancerGenome": false,
    "crossReferences": [
      {
        "id": 1451251583,
        "resource": "URL",
        "resourceId": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
        "_url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
        "version": 0
      }
    ],
    "descriptiveVideoId": "bO6Kk6hx78Q",
    "dosingInformation": false,
    "guidelineGenes": [],
    "hasTestingInfo": false,
    "history": [
      {
        "id": 1451251622,
        "date": "2020-08-19T00:00:00-07:00",
        "type": "Create",
        "version": 0
      },
      {
        "id": 1451613160,
        "date": "2021-12-10T11:11:00.330-08:00",
        "description": "Added video",
        "type": "Update",
        "version": 0
      }
    ],
    "literature": [
      {"id":15105062,"title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080882","crossReferences":[{"id":1451837598,"resource":"PubMed Central","resourceId":"PMC8080882","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080882"},{"id":1451090662,"resource":"PubMed","resourceId":"32189324","_url":"https://www.ncbi.nlm.nih.gov/pubmed/32189324"},{"id":1451090663,"resource":"DOI","resourceId":"10.1002/cpt.1830","_url":"http://dx.doi.org/10.1002%2Fcpt.1830"}],"objCls":"Literature","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}]}
    ],
    "pediatric": false,
    "recommendation": false,
    "relatedAlleles": [],
    "relatedChemicals": [
      {
        "objCls": "Chemical",
        "id": "PA166049185",
        "name": "aceclofenac",
        "version": 6
      },
      {
        "objCls": "Chemical",
        "id": "PA448497",
        "name": "aspirin",
        "version": 15
      },
      {
        "objCls": "Chemical",
        "id": "PA449293",
        "name": "diclofenac",
        "version": 9
      },
      {
        "objCls": "Chemical",
        "id": "PA166128206",
        "name": "dipyrone",
        "version": 7
      },
      {
        "objCls": "Chemical",
        "id": "PA449982",
        "name": "indomethacin",
        "version": 9
      },
      {
        "objCls": "Chemical",
        "id": "PA164769031",
        "name": "lumiracoxib",
        "version": 4
      },
      {
        "objCls": "Chemical",
        "id": "PA450572",
        "name": "nabumetone",
        "version": 9
      },
      {
        "objCls": "Chemical",
        "id": "PA450595",
        "name": "naproxen",
        "version": 11
      }
    ],
    "relatedGenes": [
      {
        "objCls": "Gene",
        "id": "PA126",
        "symbol": "CYP2C9",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "version": 7876
      }
    ],
    "source": "CPIC",
    "summaryMarkdown": {
      "id": 1451251620,
      "html": "<p>There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.</p>\n",
      "version": 0
    },
    "terms": [],
    "textMarkdown": {
      "id": 1451433685,
      "html": "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/\" target=\"_blank\">CPIC&reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9</a>. The CPIC authors have evaluated therapeutic dose recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes. They conclude that there is insufficient evidence to provide a recommendation to guide clinical practice at this time.</p>\n<h3 id=\"march-2020\">March 2020</h3>\n<ul>\n<li>\n<p>The <a rel=\"noopener noreferrer\" href=\"https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830\" target=\"_blank\">CPIC guideline regarding for <em>CYP2C9</em> and Nonsteroidal Anti-inflammatory Drugs</a> is published in Clinical Pharmacology and Therapeutics.</p>\n</li>\n<li>\n<p>These guidelines are applicable to:</p>\n<ul>\n<li>\n<p>pediatric patients</p>\n</li>\n<li>\n<p>adult patients</p>\n</li>\n</ul>\n</li>\n<li>\n<p>Excerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:</p>\n<ul>\n<li>&quot;Aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen. Table S9 includes evidence linking CYP2C9 genotype to aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen phenotype. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C; Table S20).&quot;</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2C9</em> and NSAIDs Therapy</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324-supplement.pdf\" target=\"_blank\">2020 supplement</a></li>\n</ul>\n</li>\n</ul>\n",
      "version": 0
    },
    "userId": "lgong",
    "version": 2
  }
}